Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22633624)

  • 1. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).
    Minard-Colin V; Ichante JL; Nguyen L; Paci A; Orbach D; Bergeron C; Defachelles AS; André N; Corradini N; Schmitt C; Tabone MD; Blouin P; Sirvent N; Goma G; Geoerger B; Oberlin O
    Eur J Cancer; 2012 Oct; 48(15):2409-16. PubMed ID: 22633624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
    J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.
    Kuttesch JF; Krailo MD; Madden T; Johansen M; Bleyer A;
    Pediatr Blood Cancer; 2009 Oct; 53(4):590-3. PubMed ID: 19533657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
    Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
    Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.
    Carli M; Perilongo G; di Montezemolo LC; De Bernardi B; Ceci A; Paolucci G; Pianca C; Calculli G; Di Tullio MT; Grotto P
    Cancer Treat Rep; 1987 May; 71(5):525-7. PubMed ID: 3567976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
    Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
    Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y; Hashimoto K; Ando M; Yonemori K; Yamamoto H; Kodaira M; Yunokawa M; Shimizu C; Tamura K; Hosono A; Makimoto A; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):391-7. PubMed ID: 22806306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
    Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
    Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
    Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
    Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK; Banavali S
    Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
    Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
    Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.